BON Stock Chart & Stats
€26.20
€0.50(1.89%)
At close: 4:00 PM EDT
€26.20
€0.50(1.89%)
Day’s Range― - ―
52-Week Range€23.15 - €31.35
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€458.99M
Enterprise Value€344.59
Total Cash (Recent Filing)€79.34M
Total Debt (Recent Filing)€31.48M
Price to Earnings (P/E)14.0
Beta-0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,545,408
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.35
Price to Sales (P/S)1.06
P/FCF Ratio17.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Boiron financial flexibility to fund operations, absorb periods of weaker demand, and support product investment without relying heavily on additional borrowing.
Positive Cash GenerationRecurring positive operating and free cash flow indicates that the core business converts activity into funding, supporting reinvestment and shareholder distributions while reducing dependence on external capital.
Profitability RecoveryThe sharp margin recovery and rebound in operating profitability show that Boiron retains earnings leverage when conditions improve, providing a stronger profitability base despite uneven revenue performance.
Bears Say
Severe Revenue ContractionA severe reported decline in sales weakens visibility into demand and makes it harder to assess the durability of the company’s earnings, operating scale, and ability to sustain investment.
Inconsistent Revenue TrendRepeatedly uneven or declining revenue suggests challenges in maintaining product demand and market momentum, limiting confidence in medium-term growth and reducing operating planning predictability.
Volatile Free Cash FlowAlthough cash flow remains positive, sharp year-to-year volatility makes cash conversion less predictable and may constrain the timing or scale of reinvestment and shareholder-return decisions.
BON FAQ
What was Boiron SA’s price range in the past 12 months?
Boiron SA lowest stock price was €23.15 and its highest was €31.35 in the past 12 months.
What is Boiron SA’s market cap?
Boiron SA’s market cap is €458.99M.
When is Boiron SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Boiron SA’s earnings last quarter?
Currently, no data Available
Is Boiron SA overvalued?
According to Wall Street analysts Boiron SA’s price is currently Overvalued.
Does Boiron SA pay dividends?
Boiron SA does not currently pay dividends.
What is Boiron SA’s EPS estimate?
Boiron SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boiron SA have?
Boiron SA has 17,545,408 shares outstanding.
What happened to Boiron SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Boiron SA?
Currently, no hedge funds are holding shares in DE:BON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boiron SA
Boiron S.A. is a global pharmaceutical company specializing in the production and distribution of homeopathic remedies across France, Europe, North America, and other international markets. Its extensive product portfolio encompasses a range of non-prescription, proprietary, and well-known branded homeopathic treatments. Noteworthy branded offerings include Oscillococcinum, designed to alleviate flu-like symptoms such as fever, chills, headaches, and body aches; Stodal and Stodaline, formulated for cough relief; Arnigel, providing topical support for minor, closed-wound traumas; Camilia, a solution for infant teething discomfort; and Sédatif PC, aimed at managing anxiety, emotional distress, and mild sleep disturbances. Furthermore, its homeopathic range features Coryzalia for addressing cold symptoms and rhinitis; Homéoptic, which targets eye discomfort and irritation in both adults and children; and Homéovox, developed for vocal issues. Beyond its core homeopathic line, Boiron also supplies dietary supplements; Dermoplasmine products (stick, balm, and mousse) for dry skin and lips; Mag' Nuit, an aid for promoting sleep; Arnitrosium for joint pain management; Castor Equi Boiron ointment for cracked skin; and Storinyl syrup for cold symptoms. The company's diverse inventory extends to herbal remedies, exemplified by Canephron, which supports increased urine production and improved urinary tract function; moisturizing lotions for babies; and medical devices, such as COVID-19 self-testing kits and rapid antigen tests. Boiron distributes its extensive product catalog through a comprehensive network encompassing distribution centers, independent pharmacies, pharmacy chains, wholesale partners, grocery and drugstores, specialized health food outlets, and various online retail platforms. Established in 1932, Boiron S.A. maintains its corporate headquarters in Messimy, France.